| 1.
図書 |
図書
|
鈴木榮一研究代表
|
||||||
| 2.
論文(リポジトリ) |
論文(リポジトリ)
|
山口, 義文 ; 新保, 俊光 ; 高橋, 正明 ; 若林, 昌哉 ; 吉澤, 弘久 ; 鈴木, 栄一 ; 荒川, 正昭
|
||||||
| 3.
論文(リポジトリ) |
論文(リポジトリ)
|
長谷川, 尚 ; 渡辺, 武 ; 黒田, 毅 ; 鈴木, 栄一 ; 中野, 正明 ; 荒川, 正昭
|
||||||
| 4.
論文(リポジトリ) |
論文(リポジトリ)
|
野沢, 悟 ; 伊藤, 聡 ; 石川, 肇 ; 遠山, 知香子 ; 中園, 清 ; 村沢, 章 ; 鈴木, 栄一 ; 荒川, 正昭
|
||||||
| 5.
論文(リポジトリ) |
論文(リポジトリ)
|
吉澤, 弘久 ; 松本, 尚也 ; 望月, 博史 ; 栗山, 英之 ; 各務, 博 ; 鈴木, 栄一 ; 下条, 文武
概要:
A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion
…
of peripheral blood stem-cells (PBSCs) was conducted to determine the maximum-tolerated dose (MTD) of ICE. Twenty-seven patients with SCLC (LD : 9, ED : 18) were treated with ifosfamide (3000-9000mg/m^2, 24-hour-infusion), carboplatin (300-400mg/m^2), and etoposide (300mg/m^2) followed by subcutaneous injection of filgrastim (75μg/day) through day 4 to the day of PBSC collection. PBSC were harvested when the WBC count reached ≧5×10^9/L. The leukapheresis product was cryopreserved and reinfused on day 4 of the next cycle, which was started 48 hours after the last PBSC collection. The ifosfamide dose was escalated as follows : 3000mg/m^2 (level 1), 5000mg/m^2 (level 2), 7000mg/m^2 (level 3), 9000mg/m^2 (level 4). Patients with LD were treated with concurrent radiotherapy at 1.5 Gy twice daily for the initial 3 weeks to a total dose of 45Gy and MTD, defined separately. Patients were evaluated for hematologic and non-hematologic toxicity, actual dose intensities, as well as response to the therapy. The maximum-tolerated dose (MTD) was defined as the dose level at which the level produced more than 5 days of grade 4 myelosuppression or non-hematologic toxicity greater than grade 3 in two thirds of the patients. For ED cases, MTD was level 4 and the recommended dose of ifosfamide was 7000mg/m^2. For LD cases, the recommended dose of ifosfamide was 5000mg/m^2. The dose limiting toxicity of multicyclic ICE was hematologic toxicity and CNS toxicity which manifested as ataxia. Tumor responses were seen in all patients, with 14 patients showing a complete response. The actual total dose-intensity at the recommended dose level was 2.2 and 1.74, for ED and LD, respectively, compared with previously reported ICE regimens. PBSC support for dose-intensive ICE regimen permitted dose escalation of ifosfamide with a mean interval of 16-17 days. We conclude this regimen is well tolerated, with acceptable hematological and non-hematological toxicity.
続きを見る
|
||||||
| 6.
論文(リポジトリ) |
論文(リポジトリ)
|
鈴木, 栄一
|
||||||
| 7.
論文(リポジトリ) |
論文(リポジトリ)
|
阿部, 浩一 ; 鴨井, 久司 ; 江部, 達夫 ; 外山, 孚 ; 鈴木, 栄一 ; 鈴木, 一郎
|
||||||
| 8.
論文(リポジトリ) |
論文(リポジトリ)
|
佐藤, 英夫 ; 奥村, 弘史 ; 広瀬, 慎太郎 ; 大渕, 雄子 ; 黒田, 毅 ; 中野, 正明 ; 鈴木, 栄一 ; 荒川, 正昭
|
||||||
| 9.
論文(リポジトリ) |
論文(リポジトリ)
|
小山, 裕子 ; 石塚, 康夫 ; 斎藤, 亮彦 ; 広瀬, 慎太郎 ; 長谷川, 尚 ; 中野, 正明 ; 鈴木, 栄一 ; 荒川, 正昭
|
||||||
| 10.
論文(リポジトリ) |
論文(リポジトリ)
|
浮須, 潤子 ; 山田, 尚志 ; 須田, 剛士 ; 高橋, 達 ; 朝倉, 均 ; 長谷川, 隆志 ; 鈴木, 栄一
|
